Genvec, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

USA As Represented by Secretary of the Navy

The United States of America As Represented by the Department of Health

Georgetown University

International Aids Vaccine Initiative

Other

Cornell University

The Scripps Research Institute

Human Genome Sciences, Inc.

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Aronex Pharmaceuticals, Inc.

Genvex, Inc.

C Richter King

Douglas E Brough

Joseph T Bruder

Imre Kovesdi

Stuart A Aaronson

Jason G D Gall

Matthias H Kraus

Duncan L McVey

Steven M Ruben

Gary J Nabel

Paul E Young

Zhi-yong Yang

Dajun Yang

Bimal Chakrabarti

Feng-Di Lung

Yue Huang

John S Moore

Christopher Lee Parks

Johannes H Voigt

Terrence R Burke, Jr

Thomas J Wickham

Cheng Cheng

Denise Louise Doolan

Keith Limbach

Daniel John Carucci

Peter P Roller

Lisa Wei

Martha Sedegah

Michael P Caulfield

Walter R Weiss

Joao Carlos Aguair

Ian A Wilson

Wing-Pui Kong

Robert E Bird

Ivo Lorenz

Ling Xu

Andrew B Ward

Lan Wu

Andre Marozsan

Simon Hoffenberg

Marvin J Grubman

Damodar R Ettyreddy

Thomas L Richie

John Neilan

Rogier W Sanders

Zhu-jun Yao

Albert Cupo

Zengguang Wang, Legal Representative

Rogier Sanders

Mia Hijazi

Mohammed Zuber

Hansi Dean

P J Klasse

Ya-Qui Long

Jean-Philippe Julien

Ya-Qiu Long

Mai Hijazi

Jasper J Schaible

Philip G Kasprzyk

William J Enright

Lan VRC/NIAID/NIH Wu

Per Johan Klasse

Michael Caulfield

Jean-Phillippe Julien

John Moore

The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.

Modified serotype 28 adenoviral vectors

The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.

Method for propagating adenoviral vectors encoding inhibitory gene products

The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

HIV-1 envelope glycoprotein

The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.

Malaria antigen screening method

The invention relates to generating a vaccine based on immunogens from viral particles that initially have replication competency but are then inactivated by chemical, biophysical or other methods. The components of this vaccine may be a non-HIV enveloped virus that contains and expresses a gene related to the HIV Envelope gene such that the Envelope protein is expressed on the surface of viral particles. These viral particles may be further treated to reduce their replication competency. The vaccine further may contain components to improve its immunogenicity, tolerability, stability and ease of manufacture.

Viral particles derived from an enveloped virus

The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding acircumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding aapical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.

Adenoviral vector-based malaria vaccines

The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such asnucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.

The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.

Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen

The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding anantigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.

Adenoviral vector-based foot-and-mouth disease vaccine

The invention provides a composition comprising four adenoviral vectors, each comprising a nucleic acid sequence encoding a clade A HIV Env protein, a clade B HIV Env protein, a clade C HIV Env protein, and a clade B HIV Gag-Pol fusion protein, respectively. The invention also provides a method of inducing an immune response against HIV-1 in an animal comprising administering the composition to the animal.

HIV vaccines based on adenoviral vectors encoding Env from multiple clades of HIV

The isolation, cloning and characterization of a human gene related to but distinct from EGF receptor gene has been described. Nucleotide sequence of the gene and amino acid sequence of the polypeptide encoded by the gene have been determined. The use of the nucleic acid probes and antibodies having specific binding affinity with said polypeptide for diagnostic and therapeutic purposes have also been described.

Human gene related to but distinct from EGF receptor gene

Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use

Growing community of inventors

New York, NY, United States of America

C Richter King